Sun Pharma shares slip 5% as pharma major is stopped from launching Leqselvi drug; here is all you need to know 

"As a result of the court decision, Sun is stopped from launching Leqselvi until a subsequent favorable court decision or until the expiry of the patent in the lawsuit, whichever is earlier," the filing added. 

The company said, "We respectfully disagree with and intend to immediately appeal this decision."

Leqselvi is commonly used to treat severe alopecia areata. Alopecia areata is a type of hair loss that occurs when your immune system mistakenly attacks your hair follicles, which is where hair growth begins.

Basic earnings per share (EPS) for the September 2024 quarter stood at ₹12.7 against ₹9.9 in the year-ago period. 

The pharma major said its EBITDA came in ₹3,939 crore (including other operating revenues), up 23.9% YoY, with a resulting EBITDA margin of 29.6%. 

Dilip Shanghvi, Chairman and Managing Director of the Company, said, “Sun has recently strengthened its specialty pipeline through an agreement with Philogen for commercialising late-stage candidate Fibromun, upon approval. With Fibromun, our product basket for dermatologists has expanded further. We shall continue to leverage our strong cash position to strengthen our pipeline with products that are close to market.”

"Our API business imparts the benefits of vertical integration and continuity of supply chain for our formulations business. We continue to focus on increasing API supply for captive consumption of key products," the company said in its earnings release.